{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:05:10Z","timestamp":1777633510194,"version":"3.51.4"},"reference-count":86,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2020,1,27]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Neuropathies of the peripheral and autonomic nervous systems affect up to half of all people\nwith diabetes mellitus, and are major risk factors for foot ulceration, amputation and cardiovascular\ndysfunction. Peripheral neuropathies manifest with either painful or painless symptoms, but many patients\nexperience both. Once diagnosed appropriately, painful diabetic neuropathy management presents\na unique challenge for physicians and should be considered as a syndrome, clinically distinct from diabetic\nperipheral neuropathy. The aetiology is multifactorial: metabolic changes in diabetes may directly\naffect neural tissue and neurodegenerative changes are precipitated by compromised nerve vascular\nsupply. Metabolic changes include the elevated polyol pathway activity, the increased oxidative stress,\nthe formation of advanced glycation and lipoxidation end products, and various pro-inflammatory\nchanges. These mechanisms work in combination and interact in a mutually facilitatory fashion. This\nreview focuses on the current therapies for the management of peripheral and cardiovascular autonomic\nneuropathy and of painful neuropathy as a distinct entity, based on the current knowledge of diabetic\nneuropathy. Moreover, the role of ACE inhibition has been explored in the treatment of Cardiovascular\nAutonomic Neuropathy.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570161117666190521101342","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T04:11:18Z","timestamp":1558411878000},"page":"158-171","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Treatment of Diabetic Cardiovascular Autonomic, Peripheral and Painful Neuropathy. Focus on the Treatment of Cardiovascular Autonomic Neuropathy with ACE Inhibitors"],"prefix":"10.2174","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0236-8760","authenticated-orcid":true,"given":"Triantafyllos","family":"Didangelos","sequence":"first","affiliation":[{"name":"Diabetes Center, 1st Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, \u2018\u2019AHEPA\u2019\u2019 Hospital, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3901-4405","authenticated-orcid":true,"given":"Aristidis","family":"Veves","sequence":"additional","affiliation":[{"name":"Center for Regenerative Therapeutics, The Joslin-Beth Israel Deaconess Foot Center, Beth Israel Deaconess Medical Center, Boston, MA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"245","volume":"7","author":"Shaw J.E.","year":"1999","unstructured":"Shaw J.E.; Zimmet P.Z.; Epidemiology of diabetic neuropathy. Diabetes Rev 1999,7,245-252","journal-title":"Diabetes Rev"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2337\/dc11-1108","volume":"34","author":"Abbott C.A.","year":"2011","unstructured":"Abbott C.A.; Malik R.A.; van Ross E.R.; Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the UK. Diabetes Care 2011,34,2220-2224","journal-title":"Diabetes Care"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2337\/diacare.16.8.1187","volume":"16","author":"Veves A.","year":"1993","unstructured":"Veves A.; Manes C.; Murray H.J.; Painful neuropathy and foot ulceration in diabetic patients. Diabetes Care 1993,16,1187-1189","journal-title":"Diabetes Care"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0168-8227(99)00112-6","volume":"47","author":"Galer B.S.","year":"2000","unstructured":"Galer B.S.; Gianas A.; Jensen M.P.; Painful diabetic polyneuropathy: Epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000,47,123-128","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.2337\/diacare.26.6.1790","volume":"26","author":"Gordois A.","year":"2003","unstructured":"Gordois A.; Scuffham P.; Shearer A.; The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003,26,1790-1795","journal-title":"Diabetes Care"},{"key":"ref=6","author":"Didangelos T.","unstructured":"Didangelos T.; Doupis J.; Veves A.;  Oxidative stress in diabetes mellitus and possible interventions in obrosova I, Stevens M., Yorek M (eds.), Studies in Diabetes, Oxidative Stress in Applied Basic Research and Clinical Practice, \u00a9Springer Science+Business Media New York 2014, pp 237-61"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2174\/138161208784139774","volume":"14","author":"Sugimoto K.","year":"2008","unstructured":"Sugimoto K.; Yasujima M.; Yagihashi S.; Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des 2008,14,953-961","journal-title":"Curr Pharm Des"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3109\/10715762.2013.806798","volume":"47","year":"2013","unstructured":"Rattan SI, Grune T, Trougakos IP. Molecular effects of advanced glycation end products on cell signalling pathways, ageing and pathophysiology. Free Radic Res Nedi\u0107 O12013,47(Suppl. 1),28-38","journal-title":"Free Radic Res"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.2337\/db09-0320","volume":"58","author":"Duran-Jimenez B","year":"2009","unstructured":"Duran-Jimenez B; Dobler D; Advanced glycation end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes. Diabetes Moff att S, et al2009,58,2893-2903","journal-title":"Diabetes"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.numecd.2013.04.004","volume":"23","author":"Chilelli N.C.","year":"2013","unstructured":"Chilelli N.C.; Burlina S.; Lapolla A.; AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: A \u201cglycoxidation-centric\u201d point of view. Nutr Metab Cardiovasc Dis 2013,23(10),913-919","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tem.2011.12.004","volume":"23","author":"Kim B.","year":"2012","unstructured":"Kim B.; Feldman E.L.; Insulin resistance in the nervous system. Trends Endocrinol Metab 2012,23,133-141","journal-title":"Trends Endocrinol Metab"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/15438600490424541","volume":"5","author":"Sima A.A.","year":"2004","unstructured":"Sima A.A.; Zhang W.; Grunberger G.; Type 1 diabetic neuropathy and C-peptide. Exp Diabesity Res 2004,5,65-77","journal-title":"Exp Diabesity Res"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1529-8027.2009.00237.x","volume":"14","author":"Vincent A.M.","year":"2009","unstructured":"Vincent A.M.; Hinder L.M.; Pop-Busui R.; Feldman E.L.; Hyperlipidemia: A new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst 2009,14,257-267","journal-title":"J Peripher Nerv Syst"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.2337\/db08-1771","volume":"58","author":"Wiggin T.D.","year":"2009","unstructured":"Wiggin T.D.; Sullivan K.A.; Pop-Busui R.; Amato A.; Sima A.A.; Feldman E.L.; Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 2009,58,1634-1640","journal-title":"Diabetes"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1677\/JOE-09-0370","volume":"207","author":"McCall K.D.","year":"2010","unstructured":"McCall K.D.; Holliday D.; Dickerson E.; Phenylmethimazole blocks palmitate-mediated induction of inflammatory cytokine pathways in 3T3L1 adipocytes and RAW 264.7 macrophages. J Endocrinol 2010,207,343-353","journal-title":"J Endocrinol"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11892-013-0375-y","volume":"13","author":"Lontchi-Yimagou E.","year":"2013","unstructured":"Lontchi-Yimagou E.; Sobngwi E.; Matsha T.E.; Kengne A.P.; Diabetes mellitus and inflammation. Curr Diab Rep 2013,13(3),435-444","journal-title":"Curr Diab Rep"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/oby.2010.193","volume":"19","author":"Doupis J.","year":"2011","unstructured":"Doupis J.; Rahangdale S.; Gnardellis C.; Pena S.E.; Malhotra A.; Veves A.; Effects of diabetes and obesity on vascular reactivity, inflammatory cytokines and growth factors. Obesity 2011,19(4),729-735","journal-title":"Obesity"},{"key":"ref=18","first-page":"561-8","volume":"15; 122","year":"1995","unstructured":"The effect of intensive diabetes therapy on the development and progression of neuropathy. The diabetes control and complications trial research group. Ann Intern Med 1995,15; 122(8),561-8","journal-title":"Ann Intern Med"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa032782","volume":"352","author":"Tesfaye S.","year":"2005","unstructured":"Tesfaye S.; Chaturvedi N.; Eaton S.E.M.; Vascular risk factors and diabetic Neuropathy. N Engl J Med 2005,352,341-350","journal-title":"N Engl J Med"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s11892-012-0278-3","volume":"12","author":"Papanas N.","year":"2012","unstructured":"Papanas N.; Ziegler D.; Prediabetic neuropathy: Does it exist? Curr Diab Rep 2012,12,376-382","journal-title":"Curr Diab Rep"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.2337\/dc07-1796","volume":"31","author":"Ziegler D.","year":"2008","unstructured":"Ziegler D.; Rathmann W.; Dickhaus T.; Meisinger C.; Mielk A.; Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy. Diabetes Care 2008,31,464-469","journal-title":"Diabetes Care"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s00125-004-1617-y","volume":"48","author":"Witte D.R.","year":"2005","unstructured":"Witte D.R.; Tesfaye S.; Chaturvedi N.; Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia 2005,48,164-171","journal-title":"Diabetologia"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2337\/diaclin.23.1.9","volume":"23","author":"Boulton A.J.M.","unstructured":"Boulton A.J.M.; Management of diabetic peripheral neuropathy. Clin Diabetes ,23,9-15","journal-title":"Clin Diabetes"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJM199507133330203","volume":"333","author":"Partanen J.","year":"1995","unstructured":"Partanen J.; Niskanen L.; Lehtinen J.; Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995,333,89-94","journal-title":"N Engl J Med"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/B978-0-444-53480-4.00005-9","volume":"126","author":"Didangelos T.","year":"2014","unstructured":"Didangelos T.; Doupis J.; Veves A.; Painful diabetic neuropathy: Clinical aspects. Handb Clin Neurol 2014,126,53-61","journal-title":"Handb Clin Neurol"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2337\/dc09-1941","volume":"33","author":"Albers J.W.","year":"2010","unstructured":"Albers J.W.; Herman W.H.; Pop-Busui R.; Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventionsand Complications (EDIC) Study. Diabetes Care 2010,33,1090-1096","journal-title":"Diabetes Care"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1161\/CIRCULATIONAHA.108.837369","volume":"119","author":"Pop-Busui R.","year":"2009","unstructured":"Pop-Busui R.; Low P.A.; Waberski B.H.; Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: The Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications study (DCCT\/EDIC). Circulation 2009,119,2886-2893","journal-title":"Circulation"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0026-0495(96)90180-8","volume":"45","author":"Linn T.","year":"1996","unstructured":"Linn T.; Ortac K.; Laube H.; Federlin K.; Intensive therapy in adult insulin-dependent diabetes mellitus is associated with improved insulin sensitivity and reserve: A randomized, controlled, prospective study over 5 years in newly diagnosed patients. Metabolism 1996,45,1508-1513","journal-title":"Metabolism"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","year":"1998","unstructured":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet UK Prospective Diabetes Study (UKPDS) Group1998,352,837-853","journal-title":"Lancet"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","year":"2008","unstructured":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med The ADVANCE Collaborative Group2008,358,2560-2572","journal-title":"N Engl J Med"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","volume":"376","author":"Ismail-Beigi F.","year":"2010","unstructured":"Ismail-Beigi F.; Craven T.; Banerji M.A.; Effect of intensive treatment of hyperglycemia on micro vascular outcomes in type 2 diabetes: an analysis of the ACCORD randomized trial. Lancet 2010,376,419-430","journal-title":"Lancet"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"Duckworth W.","year":"2009","unstructured":"Duckworth W.; Abraira C.; Moritz T.; Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009,360,129-139","journal-title":"N Engl J Med"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1155\/EDR.2003.271","volume":"4","author":"Pittenger G.","year":"2003","unstructured":"Pittenger G.; Vinik A.; Nerve growth factor and diabetic neuropathy. Exp Diabesity Res 2003,4,271-285","journal-title":"Exp Diabesity Res"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.284.17.2215","volume":"284","author":"Apfel S.C.","year":"2000","unstructured":"Apfel S.C.; Schwartz S.; Adornato B.T.; Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000,284(17),2215-2221","journal-title":"JAMA"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.2040-1124.2010.00083.x","volume":"2","author":"Tesfaye S.","year":"2011","unstructured":"Tesfaye S.; Recent advances in the management of diabetic distal symmetrical polyneuropathy. J Diabetes Investig 2011,2(1),33-42","journal-title":"J Diabetes Investig"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"896","DOI":"10.2337\/dc06-1699","volume":"30","author":"Casellini C.M.","year":"2007","unstructured":"Casellini C.M.; Barlow P.M.; Rice A.L.; A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes Care 2007,30(4),896-902","journal-title":"Diabetes Care"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4093\/dmj.2013.37.5.375","volume":"37","author":"Bansal D.","year":"2013","unstructured":"Bansal D.; Badhan Y.; Gudala K.; Schifano F.; Ruboxistaurin for the treatment of diabetic peripheral neuropathy: A systematic review of randomized clinical trials. Diabetes Metab J 2013,37(5),375-384","journal-title":"Diabetes Metab J"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/dmrr.1239","volume":"27","author":"Spallone V.","year":"2011","unstructured":"Spallone V.; Ziegler D.; Freeman R.; Cardiovascular autonomic neuropathy indiabetes: Clinical impact, assessment, diagnosis and management. Diabetes Metab Res Rev 2011,27,639-653","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2337\/diacare.7.5.447","volume":"7","author":"Pfeifer M.A.","year":"1984","unstructured":"Pfeifer M.A.; Weinberg C.R.; Cook D.L.; Autonomic neural dysfunction in recently diagnosed diabetic subjects. Diabetes Care 1984,7,447-453","journal-title":"Diabetes Care"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.2337\/diacare.26.6.1895","volume":"26","author":"Maser R.E.","year":"2003","unstructured":"Maser R.E.; Mitchell B.D.; Vinik A.I.; The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: A meta-analysis. Diabetes Care 2003,26,1895-1901","journal-title":"Diabetes Care"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc07-1615","volume":"31","author":"Ziegler D.","year":"2008","unstructured":"Ziegler D.; Zentai C.P.; Perz S.; Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: The MONICA\/KORA Augsburg Cohort Study. Diabetes Care 2008,31,556-561","journal-title":"Diabetes Care"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1080\/00365510802018330","volume":"68","author":"Lykke J.A.","year":"2008","unstructured":"Lykke J.A.; Tarnow L.; Parving H.H.; A combined abnormality in heart rate variation and QT corrected interval is a strong predictor of cardiovascular death in type 1 diabetes. Scand J Clin Lab Invest 2008,68,654-659","journal-title":"Scand J Clin Lab Invest"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1007\/s00125-010-1787-8","volume":"53","author":"Rennings A.J.","year":"2010","unstructured":"Rennings A.J.; Smits P.; Stewart M.W.; Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients with type 2 diabetes: a randomized, controlled trial on thiazolidinedione-induced vascular leakage. Diabetologia 2010,53,1856-1866","journal-title":"Diabetologia"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.2337\/diacare.26.7.1955","volume":"26","author":"Didangelos T.P.","year":"2003","unstructured":"Didangelos T.P.; Arsos G.A.; Karamitsos D.T.; Athyros V.G.; Karatzas N.D.; Left ventricular systolic and diastolic function in normotensive type 1 diabetic patients with or without autonomic neuropathy: A radionuclide ventriculography study. Diabetes Care 2003,26(7),1955-1960","journal-title":"Diabetes Care"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1177\/0003319713510966","volume":"65","author":"Didangelos T.P.","year":"2014","unstructured":"Didangelos T.P.; Arsos G.; Karamitsos T.; Left ventricular systolic and diastolic function in normotensive type 2 diabetic patients with or without autonomic neuropathy: A radionuclide ventriculography study. Angiology 2014,65(10),877-882","journal-title":"Angiology"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/CIRCULATIONAHA.106.634949","volume":"115","author":"Vinik A.I.","year":"2007","unstructured":"Vinik A.I.; Ziegler D.; Diabetic cardiovascular autonomic neuropathy. Circulation 2007,115,387-397","journal-title":"Circulation"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2337\/diacare.8.5.491","volume":"8","author":"Ewing D.J.","year":"1985","unstructured":"Ewing D.J.; Martyn C.N.; Young R.J.; Clarke B.F.; The value of cardiovascular autonomic function tests: 10 years\u2019 experience in diabetes. Diabetes Care 1985,8,491-498","journal-title":"Diabetes Care"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s00125-003-1032-9","volume":"46","author":"Gerritsen J","year":"2003","unstructured":"Gerritsen J; TenVoorde BJ; Dekker JM; Measures of cardiovascular autonomic nervous function: Agreement, reproducibility, and reference values in middle age and elderly subjects. Diabetologia Dekker et al2003,46(3),330-338","journal-title":"Diabetologia"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)07368-1","volume":"353","author":"Gaede P.","year":"1999","unstructured":"Gaede P.; Vedel P.; Parving H.H.; Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999,353,617-622","journal-title":"Lancet"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","volume":"348","author":"Gaede P.","year":"2003","unstructured":"Gaede P.; Vedel P.; Larsen N.; Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003,348,383-393","journal-title":"N Engl J Med"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","volume":"358","author":"Gaede P.","year":"2008","unstructured":"Gaede P.; Lund-Andersen H.; Parving H.H.; Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008,358,580-591","journal-title":"N Engl J Med"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1007\/s00125-018-4642-y","volume":"61","author":"Oellgaard J.","year":"2018","unstructured":"Oellgaard J.; Gaede P.; Rossing P.; Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. Diabetologia 2018,61,1724-1733","journal-title":"Diabetologia"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00125-016-4065-6","volume":"59","author":"Gaede P.","year":"2016","unstructured":"Gaede P.; Oellgaard J.; Carstensen B.; Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016,59,2298-2307","journal-title":"Diabetologia"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2337\/diacare.20.3.355","volume":"20","author":"Kontopoulos A.G.","year":"1997","unstructured":"Kontopoulos A.G.; Athyros V.G.; Didangelos T.P.; Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care 1997,20(3),355-361","journal-title":"Diabetes Care"},{"key":"ref=55","first-page":"201","volume":"53","author":"Athyros V.G.","year":"1998","unstructured":"Athyros V.G.; Didangelos T.P.; Karamitsos D.T.; Long-term effect of converting enzyme inhibition on circadian sympathetic and parasympathetic modulation in patients with diabetic autonomic neuropathy. Acta Cardiol 1998,53(4),201-209","journal-title":"Acta Cardiol"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdiacomp.2005.05.002","volume":"20","author":"Didangelos T.P.","year":"2006","unstructured":"Didangelos T.P.; Arsos G.A.; Karamitsos D.T.; Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy. J Diabetes Complications 2006,20(1),1-7","journal-title":"J Diabetes Complications"},{"key":"ref=57","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6719239","volume":"2017","author":"Didangelos T.","year":"2017","unstructured":"Didangelos T.; Tziomalos K.; Margaritidis C.; Efficacy of administration of an angiotensin converting enzyme inhibitor for two years on autonomic and peripheral neuropathy in patients with diabetes mellitus. J Diabetes Res 2017,2017","journal-title":"J Diabetes Res"},{"key":"ref=58","first-page":"163","volume":"10","author":"Selby J.V.","year":"2004","unstructured":"Selby J.V.; Peng T.; Karter A.J.; High rates of co-occurrence of hypertension, elevated low-density lipoprotein cholesterol, and diabetes mellitus in a large managed care population. Am J Manag Care 2004,10(part 2),163-170","journal-title":"Am J Manag Care"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jdiacomp.2015.10.018","volume":"30","author":"Ziegler D.","year":"2016","unstructured":"Ziegler D.; Low P.A.; Freeman R.; Tritschler H.; Vinik A.I.; Predictors of improvement and progression of diabetic polyneuropathy following treatment with \u03b1-lipoic acid for 4 years in the NATHAN 1 trial. J Diabetes Complications 2016,30(2),350-356","journal-title":"J Diabetes Complications"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF03257394","volume":"7","author":"A. Papageorgiou","year":"1994","unstructured":"A. Papageorgiou; A Karayiannis.; V Athyros.; A comparative study of the efficacy and safety of quinapril and lisinopril in patients with mild to moderate hypertension. Drug Investig 1994,7(1),13-17","journal-title":"Drug Investig"},{"key":"ref=61","author":"Yozgatli K.","year":"2018","unstructured":"Yozgatli K.; Lefrandt J.D.; Noordzij M.J.; Accumulation of advanced glycation end products is associated with macrovascular events and glycaemic control with microvascular complications in Type 2 diabetes mellitus. Diabet Med 2018","journal-title":"Diabet Med"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.2337\/diabetes.51.11.3274","volume":"51","author":"Forbes J.M.","year":"2002","unstructured":"Forbes J.M.; Cooper M.E.; Thallas V.; Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002,51,3274-3282","journal-title":"Diabetes"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1681\/ASN.2005010062","volume":"16","author":"Forbes J.M.","year":"2005","unstructured":"Forbes J.M.; Thorpe S.R.; Thallas-Bonke V.; Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 2005,16(8),2363-2372","journal-title":"J Am Soc Nephrol"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"894","DOI":"10.2337\/diacare.25.5.894","volume":"25","author":"Adler A.I.","year":"2002","unstructured":"Adler A.I.; Stevens R.J.; Neil A.; Stratton I.M.; Boulton A.J.; Holman R.R.; UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002,25(5),894-899","journal-title":"Diabetes Care"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00044011-199815020-00005","volume":"15","author":"Didangelos T.P.","year":"1998","unstructured":"Didangelos T.P.; Athyros V.G.; Karamitsos D.T.; Effect of aldose reductase inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy. Clin Drug Investig 1998,15(2),111-121","journal-title":"Clin Drug Investig"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1056-8727(97)00121-9","volume":"12","author":"Didangelos T.P.","year":"1998","unstructured":"Didangelos T.P.; Karamitsos D.T.; Athyros V.G.; Kourtoglou G.I.; Effect of aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy over a period of 2 years. J Diabetes Complications 1998,12(4),201-207","journal-title":"J Diabetes Complications"},{"key":"ref=67","author":"Merskey H.","year":"1994","unstructured":"Merskey H.; Bogduk N.;  Classification of chronic pain: Descriptions of chronic pain syndromes and definitions of pain terms 1994","journal-title":"Classification of chronic pain: Descriptions of chronic pain syndromes and definitions of pain terms"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","volume":"70","author":"Treede R.D.","year":"2008","unstructured":"Treede R.D.; Jensen T.S.; Campbell J.N.; Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology 2008,70,1630-1635","journal-title":"Neurology"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(00)33144-0","volume":"126","author":"Pavy F.W.","year":"1885","unstructured":"Pavy F.W.; Introductory address to the discussion on the clinical aspect of glycosuria. Lancet 1885,126,1085-1087","journal-title":"Lancet"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1526-4637.2007.00347.x","volume":"9","author":"Veves A.","year":"2008","unstructured":"Veves A.; Backonja M.; Malik R.A.; Painful diabetic neuropathy: Epidemiology, natural history, early diagnosis and treatment options. Pain Med 2008,9(6),660-674","journal-title":"Pain Med"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s004150050179","volume":"245","author":"Said G.","year":"1998","unstructured":"Said G.; Bigo A.; Ameri A.; Uncommon early-onset neuropathy in diabetic patients. J Neurol 1998,245,61-68","journal-title":"J Neurol"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1046\/j.1464-5491.2002.00801.x","volume":"19","author":"Oyibo S.O.","year":"2002","unstructured":"Oyibo S.O.; Prasad Y.D.; Jackson N.J.; Jude E.B.; Boulton A.J.; The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med 2002,19(10),870-873","journal-title":"Diabet Med"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","volume":"17","author":"Attal N.","year":"2010","unstructured":"Attal N.; Cruccu G.; Baron R.; EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010,17,1113-1123","journal-title":"Eur J Neurol"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1212\/WNL.0b013e3182166ebe","volume":"76","author":"Bril V.","year":"2011","unstructured":"Bril V.; England J.; Franklin G.M.; Evidence-based guideline: Treatment of painful diabetic neuropathy. Report of the American Academy of Neurology, the American Association of Neuromuscular and electro diagnostic medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011,76,1758-1765","journal-title":"Neurology"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.pain.2004.05.001","volume":"110","author":"Rosenstock J.","year":"2004","unstructured":"Rosenstock J.; Tuchman M.; LaMoreaux L.; Sharma U.; Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pain 2004,110,628-638","journal-title":"Pain"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1212\/01.WNL.0000145767.36287.A1","volume":"63","author":"Lesser H.","year":"2004","unstructured":"Lesser H.; Sharma U.; LaMoreaux L.; Poole R.M.; Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial. Neurology 2004,63,2104-2110","journal-title":"Neurology"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jpain.2004.12.007","volume":"6","author":"Richter R.W.","year":"2005","unstructured":"Richter R.W.; Portenoy R.; Sharma U.; Relief of painful diabetic peripheral neuropathy with pregabalin: A randomized, placebo-controlled trial. J Pain 2005,6,253-260","journal-title":"J Pain"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pain.2005.02.032","volume":"115","author":"Freynhagen R.","year":"2005","unstructured":"Freynhagen R.; Strojek K.; Griesing T.; Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo controlledtrial of flexible- and fixed-dose regimens. Pain 2005,115,254-263","journal-title":"Pain"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1001\/jama.280.21.1831","volume":"280","author":"Backonja M.","year":"1998","unstructured":"Backonja M.; Beydoun A.; Edwards K.R.; Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA 1998,280,1831-1836","journal-title":"JAMA"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1526-4637.2005.00061.x","volume":"6","author":"Raskin J.","year":"2005","unstructured":"Raskin J.; Pritchett Y.L.; Wang F.; A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005,6,346-356","journal-title":"Pain Med"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1056-8727(00)00060-X","volume":"14","author":"Harati Y.","year":"2000","unstructured":"Harati Y.; Gooch C.; Swenson M.; Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications 2000,14,65-70","journal-title":"J Diabetes Complications"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0304-3959(03)00160-X","volume":"105","author":"Watson C.P.","year":"2003","unstructured":"Watson C.P.; Moulin D.; Watt-Watson J.; Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003,105,71-78","journal-title":"Pain"},{"key":"ref=83","first-page":"S63","volume":"50","author":"Ziegler D.","year":"2011","unstructured":"Ziegler D.; Low P.A.; Boulton A.J.; Antioxidant treatment with alpha-lipoic acid in diabetic polyneuropathy: A 4-year randomized double-blind trial (NATHAN 1). Diabetologia 2011,50,S63","journal-title":"Diabetologia"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S1474-4422(08)70228-X","volume":"7","author":"Backonja M.","year":"2008","unstructured":"Backonja M.; Wallace M.S.; Blonsky E.R.; NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: A randomized, double-blind study. Lancet Neurol 2008,7,1106-1112","journal-title":"Lancet Neurol"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1185\/03007990903048078","volume":"25","author":"Baron R.","year":"2009","unstructured":"Baron R.; Mayoral V.; Leijon G.; Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. Curr Med Res Opin 2009,25,1677-1687","journal-title":"Curr Med Res Opin"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.pain.2013.05.043","volume":"154","author":"Tesfaye S.","year":"2013","unstructured":"Tesfaye S.; Wilhelm S.; Lledo A.; Duloxetine and pregabalin: High-dose mono therapy or their combination? The \u201cCOMBO-DN study\u201d--a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain 2013,154(12),2616-2625","journal-title":"Pain"}],"container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/172213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T13:57:40Z","timestamp":1582293460000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/172213\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,27]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,1,27]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570161117666190521101342","relation":{},"ISSN":["1570-1611"],"issn-type":[{"value":"1570-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,27]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-11-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}